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Abstract
Background: Reactive oxygen species have been implicated in the physiopathogenesis of hypertensive end-organ
damage. This study investigated the impact of the C242T polymorphism of the p22-phox gene (CYBA) on left
ventricular structure in Brazilian hypertensive subjects.
Methods: We cross-sectionally evaluated 561 patients from 2 independent centers [Campinas (n = 441) and Vitória
(n = 120)] by clinical history, physical examination, anthropometry, analysis of metabolic and echocardiography
parameters as well as p22-phox C242T polymorphism genotyping. In addition, NADPH-oxidase activity was
quantified in peripheral mononuclear cells from a subgroup of Campinas sample.
Results: Genotype frequencies in both samples were consistent with the Hardy- Weinberg equilibrium. Subjects
with the T allele presented higher left ventricular mass/height2.7 than those carrying the CC genotype in Campinas
(76.8 ± 1.6 vs 70.9 ± 1.4 g/m2.7; p = 0.009), and in Vitória (45.6 ± 1.9 vs 39.9 ± 1.4 g/m2.7; p = 0.023) samples. These
results were confirmed by stepwise regression analyses adjusted for age, gender, blood pressure, metabolic
variables and use of anti-hypertensive medications. In addition, increased NADPH-oxidase activity was detected in
peripheral mononuclear cells from T allele carriers compared with CC genotype carriers (p = 0.03).
Conclusions: The T allele of the p22-phox C242T polymorphism is associated with higher left ventricular mass/
height2.7 and increased NADPH-oxidase activity in Brazilian hypertensive patients. These data suggest that genetic
variation within NADPH-oxidase components may modulate left ventricular remodeling in subjects with systemic
hypertension.
Keywords: p22-phox, left ventricle, hypertension, polymorphism, NADPH-oxidase
Background
Left ventricular (LV) hypertrophy is an independent pre-
dictor of cardiovascular events and is a major risk factor
for the development of heart failure in hypertensive sub-
jects [1]. Oxidative stress derived from Nicotinamide ade-
nine dinucleotide phosphate (NADPH)-oxidase has been
implicated in the physiopathogenesis of hypertensive LV
remodeling [2,3]. Among the subunits that comprise the
NADPH-oxidase system, the p22-phox is highlighted as
an essential membrane-associated factor that plays a
crucial role in the activation and stabilization of this
enzymatic complex [4]. In this regard, experimental evi-
dence showed that LV hypertrophy is accompanied by
increased myocardial p22-phox expression in aortic-
banded rats, suggesting that this protein might be
involved in hypertensive cardiac remodeling [2,5].
To date, several polymorphisms of the p22-phox gene
(CYBA) have been identified [6]. One of the most stu-
died polymorphisms of this gene is the C242T, which
predicts the nonconservative substitution of histidine-72
by a tyrosine residue [7] and has been shown to enhance
the functional activity of NADPH-oxidase [8]. However,
although numerous studies investigated the role of the
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p22-phox C242T polymorphism in cardiovascular phe-
notypes [9], a significant heterogeneity for a modulating
role of the T allele has been reported [9,10]. In addition,
little is known about the impact of this variant on the
development of hypertensive end-organ damage. Thus,
the aim of the present report was to investigate whether
the C242T p22-phox polymorphism is associated with
variation in LV structure in hypertensive subjects.
Methods
Study population
The study was carried out in 561 unrelated hypertensive
subjects from two independent centers located in distinct
states of Brazil. The Campinas sample consisted of hyper-
tensive patients from a tertiary referral clinic hospital and
comprised 441 subjects (264 women and 177 men) from
the city of Campinas, São Paulo State, with high preva-
lence of end-organ damage [11,12]. The Vitória sample
consisted of hypertensive patients from a population-
based study and comprised 120 subjects (76 women and
44 men) from the city of Vitória, Espírito Santo State
[13]. The research was carried out in accordance with the
Declaration of Helsinki of the World Medical Associa-
tion. This study was approved by the Human Research
Ethics Committee of the University of Campinas and by
the Committee for Research on Human Subjects of the
Espírito Santo Federal University. All subjects gave writ-
ten informed consent to participate.
Hypertension was defined as systolic blood pressure
≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg or
current antihypertensive medication use. Diabetes mellitus
was diagnosed if fasting blood glucose was ≥ 126 mg/dL
or when participants were taking hypoglycemic medica-
tions [14]. Coronary heart disease was diagnosed by his-
tory of myocardial infarction, acute coronary syndrome or
coronary revascularization or by evidence of cardiac ische-
mia documented by functional testing. Main exclusion
criteria were age under 18 years, significant cardiac valve
disease, hypertrophic cardiomyopathy and neoplastic
disease.
Blood pressure was measured using a validated digital
oscillometric device (HEM-705CP; Omron Healthcare,
Kyoto, Japan) with appropriate cuff sizes. Two readings
were averaged and, if they differed by more than 5 mmHg,
one additional measurement was performed and the aver-
age of the three measurements was taken.
Body mass index was calculated as body weight
divided by height squared (kg/m2). Fasting blood total
cholesterol, low-density-lipoprotein cholesterol, high-
density-lipoprotein cholesterol, triglycerides, uric acid
and glucose levels were measured using standard labora-
tory techniques. In addition, creatinine clearance was
calculated from serum and urine samples.
Echocardiography
Echocardiography studies were performed on each sub-
ject at rest in the left lateral decubitus position using a
Vivid 3 Pro (General Electric, Milwaukee, WI) apparatus
equipped with a 2.5 MHz transducer as previously
described [15,16]. LV end-diastolic and end-systolic dia-
meters, interventricular septum thickness, posterior wall
thickness and LV mass were measured in accordance
with the American Society of Echocardiography guide-
lines [17]. Relative wall thickness was computed as twice
the posterior wall thickness divided by LV end-diastolic
diameter. LV mass index was considered as LV mass/
height2.7. All the recordings were made by one physician
in the Campinas sample and by another physician in the
Vitória sample. The reproducibility of both acquiring and
measuring LV mass was determined in recordings
obtained from 10 subjects in each sample. Intraobserver
and interobserver LV mass variabilities were < 8% and <
11%, respectively.
Genotyping
Genomic DNA was extracted from peripheral blood leu-
kocytes. The p22-phox C242T polymorphism was ana-
lyzed by polymerase chain reaction and digestion with
Rsa-I restriction enzyme [18]. Quality control for these
assays was assessed by randomly selecting 40 samples to
be re-genotyped by two independent technicians.
NADPH-oxidase activity assay
NADPH-oxidase activity was assessed in peripheral
mononuclear cells (monocytes and lymphocytes) isolated
from blood samples according to Degasperi et al. [19].
Briefly, peripheral blood monocytic cells from 18 hyper-
tensive patients of the Campinas sample carrying differ-
ent p22-phox C242T genotypes (6 CC, 6 CT and 6 TT
subjects) were isolated by density gradient centrifugation
over Histopaque 1077 and washed twice with phos-
phate-buffered saline. Cells were counted in a Neubauer
chamber, and cell viability was determined by trypan
blue exclusion method. Cells were only used when viabi-
lity was greater than 98%. In order to evaluate NADPH-
oxidase activity, dihydroethidium (DHE) (Molecular
Probes Inc., Eugene, OR) was used as a sensitive probe.
For this purpose, cells (2 × 106 cells/mL) were immedi-
ately incubated with 10 μM DHE at 37°C, with or with-
out 10 μM diphenylene iodonium (DPI), a selective
inhibitor of NADPH-oxidase, and the fluorescence
intensity was quantified in a spectrofluorometer (F-4500,
Hitachi, Tokyo, Japan) using excitation and emission
wavelengths of 563 and 587 nm, respectively, and slit
widths of 5 nm, with gentle continuous stirring. The
difference between the activities measured without and
with DPI was considered as NADPH-oxidase activity.
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Statistical analysis
Data were analyzed using SPSS 15.0™. Descriptive sta-
tistical results are given as means ± SEM. The differ-
ences in genotype distributions, categorical variables as
well as Hardy-Weinberg disequilibria for polymorphism
were tested using chi-square test. Unpaired t-test was
used to compare continuous variables and to evaluate
differences in NADPH-oxidase activity between geno-
type groups. Stepwise regression analyses evaluated the
independent predictors of LV mass index. A p-value of
less than 0.05 was considered significant.
Results
Distribution and allele frequency of polymorphism
The distribution of genotypes and the frequency of alleles
of the polymorphism C242T of the p22-phox gene are
summarized in Table 1. The allele frequencies in both
samples obeyed the Hardy-Weinberg’s law. There was no
significant difference in the genotype distribution between
Campinas and Vitória samples (X2 = 1.6815; p = 0.4314).
Sample characteristics
The clinical and laboratory characteristics of hypertensive
subjects in both samples according to the C242T poly-
morphism are shown in Table 2. Given the described
dominant effect of the T allele in functional and associa-
tion studies [8,20-22] and in order to enhance statistical
power, TT subjects were added to CT ones. No differences
regarding the clinical and laboratory features were
detected between the genotype groups in both samples,
except for higher diabetes mellitus prevalence and glucose
levels in Campinas CT+TT subgroup and higher height in
Vitória CC group.
Association of the C242T polymorphism with LV structure
Echocardiography data are demonstrated in Table 3.
Hypertensive subjects carrying the T allele of the C242T
polymorphism presented higher LV mass/height2.7 than
those with the CC genotype in both samples. In addition
subjects from the Campinas sample with the T allele
exhibited higher posterior wall thickness and LV end-
diastolic diameter, compared to CC genotype carriers.
Considering that the relationships between the C242T
polymorphism and LV mass/height2.7 could be influenced
by potential confounders, stepwise regression analyses
were performed (Table 4). The 242T allele was indepen-
dently related to LV mass/height2.7 in both samples by
using a model that included gender, age, body mass index,
systolic blood pressure, diastolic blood pressure, p22-phox
C242T polymorphism, diabetes mellitus, calcium channel
blockers use and angiotensin-converting enzyme inhibi-
tors/angiotensin receptor blockers use as independent
variables.
Relationship between NADPH-oxidase activity and the
C242T polymorphism
To investigate the effects of the polymorphism on the
NADPH-oxidase activity, we used DHE as a sensitive
probe to evaluate superoxide anion production in periph-
eral blood mononuclear cells from 18 hypertensive
patients of the Campinas sample (Figure 1). Mononuclear
cells from subjects with the T allele (n = 12) presented
higher NADPH-oxidase activity (p = 0.03) than those from
individuals carrying the CC genotype (n = 6).
Discussion
Experimental evidence has indicated that activation of the
NADPH-oxidase plays a major role in the development of
LV hypertrophy induced by pressure overload [2,3]. In the
present report we found that the p22-phox C242T variant
was independently associated with higher LV mass index
in hypertensive subjects from 2 distinct Brazilian popula-
tions. Furthermore, in vitro assays demonstrated that per-
ipheral blood mononuclear cells of T allele carriers
presented higher NADPH-oxidase activity, compared
to non-carriers. Taken together, these findings suggest
that a functional p22-phox polymorphism is associated
with alterations in LV mass in hypertensive subjects,
thus extending to humans the notion that variation in
NADPH-oxidase activation might influence LV remodel-
ing induced by pressure overload.
Several studies investigated the role of the p22-phox
C242T polymorphism in cardiovascular phenotypes.
However, a significant heterogeneity for a modulating
role of the T allele in the occurrence of atherothrombotic
disease and hypertension has been reported [9,10]. In this
context, carriers of the 242T allele were reported to be
more susceptible to coronary artery disease [20], cerebro-
vascular disease [21] and hypertension [22], while other
groups described neutral or even protective effects of this
variant against such conditions [23-26]. Conversely, the
role of the C242T polymorphism as well as of other p22-
phox variants in the development of hypertensive end-
organ damage is poorly understood. Previous data from
our group demonstrated that the -930AG polymorphism
of the p22-phox was not associated with alterations in
LV structure and renal damage in Brazilian hypertensive
subjects [27]. In the present report, we provided novel
Table 1 p22-phox C242T polymorphism in patients with
hypertension
Genotype Campinas, n (%) Vitória, n (%)
TT 60 (13.6) 11 (9.2)
CT 189 (42.8) 54 (45.0)
CC 192 (43.6) 55 (45.8)
T Allele frequency 0.35 0.32 p = 0.431
C Allele frequency 0.65 0.68 X2 = 1.681
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evidence that the C242T polymorphism was associated
with higher LV mass index in hypertensive patients inde-
pendently of potential confounding factors such as age,
gender, blood pressure, metabolic variables and use of
anti-hypertensive medications. Noticeably these findings
were reproduced in 2 independent and unrelated sam-
ples, with quite different clinical features, thus strength-
ening the validity of the results. In this regard, the
Campinas sample comprised subjects with high preva-
lence of end-organ damage who attended a tertiary hos-
pital, while the Vitória sample included individuals from
a population-based study. On the other hand, given that
our functional assays demonstrated higher NADPH-
oxidase activity in mononuclear cells carrying the T
allele, it can be speculated that functional genetic varia-
tion in NADPH-oxidase components may modulate LV
remodeling in hypertensive patients. Nevertheless, it
cannot be discarded that the C242T polymorphism is in
linkage disequilibrium with another functional poly-
morphism, located in the same gene or in its vicinity.
The present study showed that NADPH-oxidase activ-
ity of mononuclear cells with the T allele was higher
than that of mononuclear cells without the T allele,
which indicates that the C242T polymorphism of p22-
phox might lead to gain of function for the NADPH-
oxidase activity. Other reports previously assessed the
functional role of this polymorphism in leukocyte
NADPH-oxidase activity, but yielded conflicting results.
For instance, studies using phorbol 12-myristate 13-
acetate (PMA) stimulation have demonstrated either
increased [8] or reduced [26,28] NADPH-oxidase activ-
ity in leucocytes carrying the T allele. The reasons for
such discrepancies are not apparent but it is possible
that differences in clinical and ethnical features among
Table 2 Characteristics of hypertensive subjects according to the C242T polymorphism
Variable Campinas p Vitória p
Genotype (N) CT + TT (249) CC (192) CT + TT (65) CC (55)
Age, years 57.2 ± 0.8 56.4 ± 0.9 0.573 54.2 ± 1.2 57.3 ± 1.2 0.078
Gender (M/F) 101/148 76/116 0.912 20/45 24/31 0.205
Weight, kg 80 ± 1 77 ± 1 0.075 80 ± 1 80 ± 2 0.727
Height, cm 160 ± 1 159 ± 1 0.318 158 ± 1 161 ± 1 0.015
Body mass index, kg/m2 31.5 ± 0.3 30.6 ± 0.4 0.118 31.9 ± 0.4 30.9 ± 0.5 0.143
Systolic BP, mmHg 148 ± 1 146 ± 1 0.457 143 ± 2 144 ± 2 0.702
Diastolic BP, mmHg 85 ± 1 86 ± 1 0.762 91 ± 2 94 ± 2 0.359
Diabetes mellitus, n (%) 81 (32) 40 (21) 0.008 10 (15) 6 (11) 0.653
Smokers, n (%) 25 (10) 21 (11) 0.885 14 (21) 7 (13) 0.305
Coronary heart disease, n (%) 36 (14) 34 (18) 0.426 2 (3) 2 (4) 0.864
LDL-cholesterol, mg/dL 112 ± 2 112 ± 2 0.829 124 ± 5 117 ± 4 0.291
HDL-cholesterol, mg/dL 51 ± 1 52 ± 1 0.748 43 ± 1 45 ± 1 0.401
Triglycerides, mg/dL 162 ± 6 148 ± 6 0.100 195 ± 13 182 ± 13 0.501
Glucose, mg/dL 116 ± 3 106 ± 3 0.030 117 ± 6 106 ± 6 0.184
Uric acid, mg/dL 5.9 ± 0.1 6.1 ± 0.1 0.344 5.5 ± 0.1 5.4 ± 0.1 0.779
Creatinine clearance rate, mL/min 88 ± 2 91 ± 2 0.409 88 ± 4 86 ± 4 0.733
Diuretics, n (%) 188 (75) 154 (80) 0.289 26 (40) 25 (45) 0.676
Calcium channel blockers, n (%) 124 (50) 97 (51) 0.956 8 (12) 7 (13) 0.944
Beta-Blockers, n (%) 117 (47) 86 (45) 0.717 15 (23) 13 (24) 0.942
ACEI or ARB, n (%) 191 (77) 153 (79) 0.526 32 (49) 19 (34) 0.151
BP - blood pressure; LDL - low-density lipoprotein; HDL - high-density lipoprotein; ACEI or ARB - angiotensin-converting enzyme inhibitors or angiotensin
receptor blockers.
Table 3 Echocardiographic features of hypertensive patients according to the C242T polymorphism
Variable Campinas p Vitória p
Genotype (N) CT + TT (249) CC (192) CT + TT (65) CC (55)
Interventricular septum, mm 10.9 ± 0.1 10.7 ± 0.1 0.089 9.1 ± 0.1 8.8 ± 0.1 0.141
Posterior wall thickness, mm 10.9 ± 0.1 10.5 ± 0.1 0.010 8.8 ± 0.1 8.7 ± 0.1 0.402
LV end-diastolic diameter, mm 50.9 ± 0.4 49.7 ± 0.4 0.047 48.8 ± 0.7 47.8 ± 0.6 0.272
Relative wall thickness 0.433 ± 0.004 0.425 ± 0.005 0.387 0.364 ± 0.005 0.362 ± 0.006 0.825
LV Mass/height 2.7, g/m2.7 76.8 ± 1.6 70.9 ± 1.4 0.009 45.6 ± 1.9 39.9 ± 1.4 0.023
LV - left ventricular.
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the studied populations might have played a role in this
regard. Conversely, although considered a stimulus for
NADPH-oxidase activation [8,26,28], PMA also induces
mitochondrial release of reactive oxygen species [29],
which could also account for the discrepant results.
Here, evaluation of NADPH-oxidase activation was per-
formed by treating mononuclear cells with DPI, which is
considered a specific inhibitor of NADPH-oxidase [30],
thus differing from the aforementioned studies. In addi-
tion, our findings agree with data showing increased
superoxide production in transgenic HL-60 cells trans-
fected with expression plasmids carrying p22-phox cDNAs
with C242T polymorphism [8], thus strengthening the
notion that this variant might induce gain of function for
the NADPH-oxidase activity.
One limitation of this study is that part of hypertensive
subjects was on medications. Some findings regarding
the impact of the polymorphism on LV mass might be,
therefore, attributable to differential effect of various
therapy regimens. However, we diminished this potential
bias by considering in multivariate models the presence
of antihypertensive medications. On the other hand, it
should be acknowledged that some variables that may
modulate LV remodeling, such as duration of hyperten-
sion and diabetes control, were not included in multivari-
ate analysis. This might constitute another potential
limitation to this study.
Conclusions
This study shows that genetic variation within p22-phox
gene is significantly associated with higher LV mass in
two independent Brazilian samples of hypertensive
patients. A more complete understanding of the bio-
chemical processes by which p22-phox alters myocardial
growth may aid in unveiling how genetic variation in
NADPH-oxidase components might modulate LV remo-
deling in hypertensive patients.
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